This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Aug 1;4(8):1110-1111.

doi: 10.1001/jamaoncol.2017.4724.

Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

Shyam A Patel¹

Affiliations

PMID: 29346477
DOI: 10.1001/jamaoncol.2017.4724

Comment

Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

Shyam A Patel. JAMA Oncol. 2018.

. 2018 Aug 1;4(8):1110-1111.

doi: 10.1001/jamaoncol.2017.4724.

Author

Shyam A Patel¹

Affiliation

¹ Department of Medicine, Divisions of Hematology and Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.

PMID: 29346477
DOI: 10.1001/jamaoncol.2017.4724

No abstract available

PubMed Disclaimer

Comment on

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, de Botton S; AG221-C-001 Study Investigators. Fathi AT, et al. JAMA Oncol. 2018 Aug 1;4(8):1106-1110. doi: 10.1001/jamaoncol.2017.4695. JAMA Oncol. 2018. PMID: 29346478 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal